{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:37:25Z","timestamp":1780763845410,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Asan Institute for Life Sciences","award":["2017-738"],"award-info":[{"award-number":["2017-738"]}]},{"DOI":"10.13039\/501100007033","name":"Eisai Korea Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00277-018-3317-6","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:36:37Z","timestamp":1522816597000},"page":"1437-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis"],"prefix":"10.1007","volume":"97","author":[{"given":"Jung Yong","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"3317_CR1","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","volume":"23","author":"SG Fisher","year":"2004","unstructured":"Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin\u2019s lymphoma. Oncogene 23:6524\u20136534. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1207843","journal-title":"Oncogene"},{"key":"3317_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7","journal-title":"Lancet Oncol"},{"key":"3317_CR3","doi-asserted-by":"publisher","unstructured":"Hong JY, Suh C, Kim WS (2016) Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Res 5. \n                    https:\/\/doi.org\/10.12688\/f1000research.8790.1","DOI":"10.12688\/f1000research.8790.1"},{"key":"3317_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW (2011) Relapsed\/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011:498\u2013505. \n                    https:\/\/doi.org\/10.1182\/asheducation-2011.1.498","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3317_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540\u20131545. \n                    https:\/\/doi.org\/10.1056\/NEJM199512073332305","journal-title":"N Engl J Med"},{"key":"3317_CR6","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol 28:4184\u20134190. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3317_CR7","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol Off J Am Soc Clin Oncol 27:1492\u20131501. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.18.7252","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3317_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/sonc.2002.34873","volume":"29","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E (2002) In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 29:12\u201314","journal-title":"Semin Oncol"},{"key":"3317_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"3317_CR10","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952. \n                    https:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"3317_CR11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31:2103\u20132109. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.46.5203","journal-title":"J Clin Oncol"},{"key":"3317_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93:403\u2013409. \n                    https:\/\/doi.org\/10.1007\/s00277-013-1879-x","journal-title":"Ann Hematol"},{"key":"3317_CR13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol Off J Am Soc Clin Oncol 17:1244. \n                    https:\/\/doi.org\/10.1200\/jco.1999.17.4.1244","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3317_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25:579\u2013586. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3317_CR15","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol Off J Am Soc Clin Oncol 32:3490\u20133496. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3317_CR16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.leukres.2014.10.001","volume":"38","author":"F Merchionne","year":"2014","unstructured":"Merchionne F, Quintana G, Gaudio F, Minoia C, Specchia G, Guarini A, Quarta G, Pavone V, Melpignano A (2014) Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leuk Res 38:1446\u20131450. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2014.10.001","journal-title":"Leuk Res"},{"key":"3317_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","volume":"57","author":"A Arcari","year":"2016","unstructured":"Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D (2016) Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma 57:1823\u20131830. \n                    https:\/\/doi.org\/10.3109\/10428194.2015.1106536","journal-title":"Leuk Lymphoma"},{"key":"3317_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","volume":"57","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL (2016) Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update. Leuk Lymphoma 57:766\u2013782. \n                    https:\/\/doi.org\/10.3109\/10428194.2015.1099647","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3317-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T03:45:04Z","timestamp":1554349504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3317-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3317"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3317-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"4 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}